CorMedix (CRMD) on Tuesday reported preliminary Q1 net sales of $39 million.
Analysts polled by FactSet expected $32.3 million.
The company raised its H1 net sales guidance to a range of $62 million to $70 million from $50 million to $60 million previously, citing larger-than-expected orders in the last week of March.
Cash and short-term investments, excluding restricted cash, amounted to around $77.5 million as of March 31, CorMedix said.
CorMedix shares were more than 20% in premarket trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.